34 results
F-1
EX-10.7
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
that causes significant injury to, or is otherwise adversely affecting, the reputation, business, assets, operations or business relationship of the Company
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model,” was designed … to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our pharmaceutical
6-K
EX-10.3
SPRC
SciSparc Ltd
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
harassment of any employee of the Company or other party in connection with the performance of the Services; or (v) causing grave injury to the business
6-K
EX-99.3
8m4uqi8i
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.2
5gs5m
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.1
h1zollkm 1u2hip20fe
9 Feb 21
SciSparc Initiates Commercial Production of its CannAmide™ Pills
8:36am
424B4
dpifyhkmdv m10yt
2 Apr 20
Prospectus supplement with pricing info
5:28pm
F-1/A
at8u dexsrge73
31 Mar 20
Registration statement (foreign) (amended)
11:31am
F-1/A
3ccqlp6j6 1dy9v
30 Mar 20
Registration statement (foreign) (amended)
12:29pm
F-1/A
qhwxvltu
26 Mar 20
Registration statement (foreign) (amended)
12:00am
F-1/A
zu67dbun5knj1 jsw
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
424B5
z7cpt7bzk
5 Dec 19
Prospectus supplement for primary offering
5:29pm
424B5
m5m 8zwnaebnr9
1 Apr 19
Prospectus supplement for primary offering
6:57am